Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Sheets Smith Wealth Management

Sheets Smith Wealth Management grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,145 shares of the company’s stock after purchasing an additional 101 shares during the period. Sheets Smith Wealth Management’s holdings in Medpace were worth $1,045,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Centaurus Financial Inc. grew its stake in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after acquiring an additional 29 shares during the period. Lindenwold Advisors INC grew its position in shares of Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after purchasing an additional 32 shares during the period. M&T Bank Corp raised its position in shares of Medpace by 1.2% during the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after purchasing an additional 37 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its stake in shares of Medpace by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after acquiring an additional 39 shares during the last quarter. Finally, Integrated Investment Consultants LLC grew its stake in Medpace by 6.0% during the 4th quarter. Integrated Investment Consultants LLC now owns 692 shares of the company’s stock valued at $230,000 after acquiring an additional 39 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $347.52 on Wednesday. The firm’s 50-day moving average is $340.00 and its two-hundred day moving average is $356.52. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The firm has a market capitalization of $10.80 billion, a PE ratio of 30.43, a price-to-earnings-growth ratio of 1.73 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The company had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.22 EPS. Analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Truist Financial cut their target price on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. TD Cowen reduced their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and cut their price objective for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Finally, UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and decreased their target price for the company from $420.00 to $350.00 in a report on Friday, September 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.